ArticleThe American journal of tropical medicine and hygiene2021
La Crosse Virus Disease in the United States, 2003-2019.
Article in The American journal of tropical medicine and hygiene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 52 citations in OpenAlex.
- The La Crosse virus M segment determines virus isolate cell-to-cell spread and virulence.bioRxiv : the preprint server for biology · 2026Article
- Ohio Amish may be disproportionately at risk for La Crosse virus infection.medRxiv : the preprint server for health sciences · 2026Article
- Replication competent La Crosse virus pseudotyped VSV vector system as vaccine and serological diagnostic reagent.Virus research · 2026Article
- Review
- The La Crosse virus Gc head domain is a major determinant of infection and pathogenesis.Journal of virology · 2025Article
- A cap-dependent endonuclease inhibitor acts as a potent antiviral agent against La Crosse virus infection.Antimicrobial agents and chemotherapy · 2025Article
- Age dependent susceptibility and immune responses to La Crosse virus infection in non-human primates.Scientific reports · 2025Article
- Validating a Bayesian Spatio-Temporal Model to Predict La Crosse Virus Human Incidence in the Appalachian Mountain Region, USA.Microorganisms · 2025Article
- Public health significance of the white-tailed deer (Odocoileus virginianus) and its role in the eco-epidemiology of tick- and mosquito-borne diseases in North America.Parasites & vectors · 2025Review
- Spatiotemporal profile of an optimal host response to virus infection in the primate central nervous system.PLoS pathogens · 2025Article
- Age-specific dynamics of neutralizing antibodies, cytokines, and chemokines in response to La Crosse virus infection in mice.Journal of virology · 2024Article
- Retinoic acid-induced differentiation and oxidative stress inhibitors increase resistance of human neuroblastoma cells to La Crosse virus-induced cell death.Journal of virology · 2024Article
- Endemic La Crosse Virus Neuroinvasive Disease in North Carolina Residents: 2000-2020.North Carolina medical journal · 2024Article
- Persistent spatial clustering and predictors of pediatric La Crosse virus neuroinvasive disease risk in eastern Tennessee and western North Carolina, 2003-2020.PLoS neglected tropical diseases · 2024Article
- Article
- Current Status of La Crosse Virus in North America and Potential for Future Spread.The American journal of tropical medicine and hygiene · 2024Review
- The Adaptive Immune Response againstViruses · 2024Review
- Parechovirus infection in human brain organoids: host innate inflammatory response and not neuro-infectivity correlates to neurologic disease.Nature communications · 2024Article
- Mosquito control by abatement programmes in the United States: perspectives and lessons for countries in sub-Saharan Africa.Malaria journal · 2024Review
- Detection of La Crosse Virus In Situ and in Individual Progeny to Assess the Vertical Transmission Potential inInsects · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
La Crosse virus (LACV) is an arthropod-borne virus that can cause a nonspecific febrile illness, meningitis, or encephalitis. We reviewed U.S. LACV surveillance data for 2003-2019, including human disease cases and nonhuman infections. Overall, 318 counties in 27 states, principally in the Great Lakes, mid-Atlantic, and southeastern regions, reported LACV activity. A total of 1,281 human LACV disease cases were reported, including 1,183 (92%) neuroinvasive disease cases. The median age of cases was 8 years (range: 1 month-95 years); 1,130 (88%) were aged < 18 years, and 754 (59%) were male. The most common clinical syndromes were encephalitis (N = 960; 75%) and meningitis (N = 219, 17%). The case fatality rate was 1% (N = 15). A median of 74 cases (range: 35-130) was reported per year. The average annual national incidence of neuroinvasive disease cases was 0.02 per 100,000 persons. West Virginia, North Carolina, Tennessee, and Ohio had the highest average annual state incidences (0.16-0.61 per 100,000), accounting for 80% (N = 1,030) of cases. No animal LACV infections were reported. Nine states reported LACV-positive mosquito pools, including three states with no reported human disease cases. La Crosse virus is the most common cause of pediatric neuroinvasive arboviral disease in the United States. However, surveillance data likely underestimate LACV disease incidence. Healthcare providers should consider LACV disease in patients, especially children, with febrile illness, meningitis, or encephalitis in areas where the virus circulates and advise their patients on ways to prevent mosquito bites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.